LyGenesis
PA - PittsburghBiotechnology
Focus: LyGenesis is a regenerative cell therapy company focused on developing treatments for end-stage liver disease and other severe conditions using cell therapy and gene therapy modalities. The company is public-stage but pre-revenue, with a highly focused pipeline centered on organ regeneration.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About LyGenesis
AI assessmentNot HiringNo open roles listed right now. Follow LyGenesis to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
LYG-LIV0001
End Stage Liver DiseaseClinical Trials (1)
NCT04496479Allogenic Hepatocyte Transplantation Into Periduodenal Lymph Nodes
Phase 2Help build intelligence for LyGenesis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.